The strength of this study is the cross-species design with pathological and functional validation to show that ECM component fibronectin could be related to key pathological aspects of AD such as toxic protein clearance, blood–brain barrier integrity, and microglial activity. This evidence concerns the gene FN1 and Alzheimer disease.